title: Testing the porphyrinogenicity of propofol in a primed rat model.
abstract: We evaluated the porphyrinogenicity of propofol in a rat model. After a pilot study had been conducted to determine an optimal dose, 48 fasting male Sprague-Dawley rats were allocated randomly to six groups. The animals in groups 1-3 received saline i.p. In groups 4-6, the animals were given allylisopropylacetamide (AIA). Twelve hours later, animals in groups 1 and 4 received saline, groups 2 and 5 were given propofol 150 mg kg-1 i.p., followed by 75 mg kg-1 3 h later, and groups 3 and 6 received phenobarbitone 50 mg kg-1 i.p. and 25 mg kg-1 i.p. The animals were anaesthetized and killed 3 h after the second drug bolus and we measured the concentration of cytochrome P450, total porphyrin content and the activity of delta-aminolaevulinic acid synthase (ALAS) in the liver. Urinary delta-aminolaevulinic acid (ALA) and porphobilinogen (PBG) concentrations were measured. Analysis of variance and the t test with Bonferroni's correction were used to compare data. The hepatic cytochrome P450 concentration in the non-primed groups varied from 28.1 to 31.1 nmol g-1; administration of AIA decreased this to 20.1-20.9 nmol g-1. Total hepatic porphyrins were between 0.78 and 1.22 nmol g-1 in the non-primed groups and between 2.71 and 3.54 nmol g-1 in the AIA-primed groups. Hepatic ALAS activity was 29.2 and 35.5 nmol h-1 g-1 in groups 1 and 2. In the primed saline group, ALAS activity was measured at 134.5 nmol h-1 g-1.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Anaesthesia, University of Heidelberg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Böhrer
authors.forename: H
authors.initials: H
authors.lastname: Schmidt
authors.forename: E
authors.initials: E
authors.lastname: Martin
authors.forename: R
authors.initials: R
authors.lastname: Lux
authors.forename: K
authors.initials: K
authors.lastname: Bolsen
authors.forename: G
authors.initials: G
authors.lastname: Goerz
mesh_terms: D000624:5-Aminolevulinate Synthetase / Q000378:metabolism; D000502:Allylisopropylacetamide; D000622:Aminolevulinic Acid / Q000652:urine; D018686:Anesthetics, Intravenous / Q000009:adverse effects*; D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D008099:Liver / Q000201:enzymology; D008297:Male; D011162:Porphobilinogen / Q000652:urine; D017094:Porphyrias, Hepatic / Q000139:chemically induced*; D011166:Porphyrins / Q000378:metabolism; D015742:Propofol / Q000009:adverse effects*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D018686:Anesthetics, Intravenous; D011166:Porphyrins; D000502:Allylisopropylacetamide; D011162:Porphobilinogen; D000622:Aminolevulinic Acid; D003577:Cytochrome P-450 Enzyme System; D000624:5-Aminolevulinate Synthetase; D015742:Propofol